par Hoffmann, Paul;Roumeguere, Thierry
;Schulman, Claude
;Van Velthoven, Roland 
Référence The New England journal of medicine, 355, 25, page (2705-2707)
Publication Publié, 2006-12



Référence The New England journal of medicine, 355, 25, page (2705-2707)
Publication Publié, 2006-12
Article révisé par les pairs
Titre: |
|
Auteur: | Hoffmann, Paul; Roumeguere, Thierry; Schulman, Claude; Van Velthoven, Roland |
Informations sur la publication: | The New England journal of medicine, 355, 25, page (2705-2707) |
Statut de publication: | Publié, 2006-12 |
Sujet CREF: | Cancérologie |
MeSH keywords: | Adjuvants, Immunologic |
BCG Vaccine | |
Carcinoma in Situ -- therapy | |
Cholesterol -- blood | |
Cytokines -- drug effects -- urine | |
Follow-Up Studies | |
Humans | |
Hydroxymethylglutaryl-CoA Reductase Inhibitors -- adverse effects | |
Neoplasm Recurrence, Local -- epidemiology | |
Retrospective Studies | |
Th1 Cells -- drug effects | |
Th2 Cells -- drug effects | |
Treatment Outcome | |
Urinary Bladder Neoplasms -- therapy | |
Note générale: | Letter |
SCOPUS: le.j | |
Langue: | Anglais |
Identificateurs: | urn:issn:0028-4793 |
info:doi/10.1056/NEJMc062714 | |
info:pii/355/25/2705 | |
info:scp/33845700951 | |
info:pmid/17183004 |